Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14240494 | 1.00 | GLP1R (0.70) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL18359104 | 1.00 | GLP1R (0.70) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL14642472 | 0.98 | GLP1R (0.67) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL22055442 | 0.98 | GLP1R (0.67) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL15085168 | 0.97 | GLP1R (0.66) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL15085169 | 0.97 | GLP1R (0.66) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL15084765 | 0.97 | GLP1R (0.66) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL15084764 | 0.97 | GLP1R (0.66) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL14642510 | 0.97 | GLP1R (0.66) | GLP1RLPAR3LPAR1NOD1TLR2 | |
| SCHEMBL14240588 | 0.96 | GLP1R (0.65) | GLP1RLPAR3LPAR1NOD1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | NITTO DENKO CORPORATION (JP) | 2017-03-23 | — | — | US | disclosed |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | GLP1R 1614/4885LPAR3 197/4885LPAR1 74/4885 |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | GLP1R 1614/4885LPAR3 197/4885LPAR1 74/4885 |
| US-20170081663-A1 | RETINOID-LIPID DRUG CARRIER | RXRA, RXRG, LRAT | GLP1R 3265/4885LPAR3 463/4885LPAR1 652/4885 |
| US-20170000893-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | GLP1R 1614/4885LPAR3 197/4885LPAR1 74/4885 |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | GLP1R 1614/4885LPAR3 197/4885LPAR1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.